Molecular imaging for personalized cancer care

Department of Radiology, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.
Molecular oncology (Impact Factor: 5.94). 03/2012; 6(2):182-95. DOI: 10.1016/j.molonc.2012.02.005
Source: PubMed

ABSTRACT Molecular imaging is rapidly gaining recognition as a tool with the capacity to improve every facet of cancer care. Molecular imaging in oncology can be defined as in vivo characterization and measurement of the key biomolecules and molecularly based events that are fundamental to the malignant state. This article outlines the basic principles of molecular imaging as applied in oncology with both established and emerging techniques. It provides examples of the advantages that current molecular imaging techniques offer for improving clinical cancer care as well as drug development. It also discusses the importance of molecular imaging for the emerging field of theranostics and offers a vision of how molecular imaging may one day be integrated with other diagnostic techniques to dramatically increase the efficiency and effectiveness of cancer care.

  • Source
    • "Additionally, advanced imaging technologies, through earlier selection of candidates for new drugs, can reduce the large attrition rate in the pharmaceutical development process. Molecular imaging may one day be integrated with other diagnostic techniques to dramatically increase the efficiency and effectiveness of cancer care (Kircher et al., 2012). Modernization of the drug development process also calls for new models of research collaboration that can improve the probability of effective target selection and target validation. "
    [Show description] [Hide description]
    DESCRIPTION: The high price of cancer drugs has become a world-wide phenomenon. In recent decades, studies have produced ample evidence of rising research and clinical testing costs underlying pharmaceutical innovations. There is a general concurrence that the current model of drug devel¬opment needs a thorough streamlining. It is also alleged that the prices of new anticancer agents seem to be decided by pharmaceutical companies, according to what the market will bear, in a producer-dominated market. Studies have noted with concern that there is a little correlation between the actual efficacy of a new drug (in terms of prolonging a patient’s life in years, or quality-adjusted life-years (QALYs) and its price. The present study is an attempt to address some major challenges which are: (i) how to increase the overall pace of innovation (R&D productivity); (ii) how to control the costs and prices of new innovative drugs; (iii) how to direct more innovation to areas where social returns are highest; and (iv) how to improve patients’ timely access to innovative medicines while balancing ‘safety’ concerns.
  • Source
    • "This strategy has been successful for certain types of cancers [10] but unfortunately not for PDAC. The reasons are multifactorial but include extensive stromal components [11] [12] [13] and the lack of uniformly expressed biomarkers [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study is to assess lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with pancreatic ductal adenocarcinoma. Magnetic resonance imaging was performed in 13 patients with known or high index of suspicion of pancreatic cancer and who were scheduled for surgical resection. Protocols included T2*-weighted imaging before and after administration of Ferumoxytol (Feraheme) for the evaluation of lymph node involvement. Eleven of the 13 patients underwent a Whipple procedure and lymph node dissection. Nodes that lacked contrast uptake were deemed malignant, and those that demonstrated homogeneous uptake were deemed benign. A total of 264 lymph nodes were resection, of which 17 were malignant. The sensitivity and specificity of LNMRI was 76.5% and 98.4% at a nodal level and 83.3% and 80% at a patient level. LNMRI demonstrated high sensitivity and specificity in patients with pancreatic ductal adenocarcinoma.
    Translational oncology 12/2013; 6(6):670-5. DOI:10.1593/tlo.13400 · 3.40 Impact Factor
  • Source
    • "A number of topics relevant to personalized cancer medicine are discussed in this issue of Molecular Oncology. From the basic biology of cancer (De Palma and Hanahan, 2012) to drug development (Hoelder et al, 2012), with connected themes, such as immunotherapy (Gajewski, 2012) and imaging (Kircher et al., 2012). Overall, these reviews take a glance into what the future of cancer medicine may look like. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research with high throughput technologies has propitiated the segmentation of different types of tumors into very small subgroups characterized by the presence of very rare molecular alterations. The identification of these subgroups and the apparition of new agents targeting these infrequent alterations are already affecting the way in which clinical trials are being conducted with an increased need to identify those patients harboring specific molecular alterations. In this review we describe some of the currently ongoing and future studies at the Institut Gustave Roussy that aim for the identification of potential therapeutic targets for cancer patients with the incorporation of high throughput technologies into daily practice including aCGH, next generation sequencing and the creation of a software that allows for target identification specific for each tumor. The initial intention is to enrich clinical trials with cancer patients carrying certain molecular alterations in order to increase the possibility of demonstrating benefit from a targeted agent. Mid and long term aims are to facilitate and speed up the process of drug development as well as to implement the concept of personalized medicine.
    Molecular oncology 03/2012; 6(2):204-10. DOI:10.1016/j.molonc.2012.02.008 · 5.94 Impact Factor
Show more


Available from